Seacoast Technologies Appoints G. Bradley Cilley as Vice President of Marketing

Share Article

Seacoast Technologies, Inc. announced today that it has appointed G. Bradley Cilley as Vice President of Marketing. Mr. CilleyÂ?s broad experience in the medical device markets will strengthen the CompanyÂ?s ability to bring its local profound hypothermia technology forward to the neurosurgical and neurocritical care markets.

Seacoast Technologies Inc., a pioneering neurosurgical and neurocritical care medical device company involved in the delivery of local and profound hypothermia to neurological tissue, today announced the appointment of G. Bradley Cilley as Vice President of Marketing.

Mr. Cilley brings over 16 years of international marketing, sales and business development experience to the Company including 9 years in a variety of management positions at CR Bard and most recently as Vice President, Medical Devices at Nexia Biotechnologies. His responsibilities at Seacoast Technologies will include product development and marketing of the Company’s three product lines, development of the neurosurgical and neurocritical care markets for these products, development of the sales and marketing organization, and strategic business development relationships.

“Seacoast Technologies is at an important stage where our first products are beginning clinical trials and are thus being introduced clinically and scientifically to the medical community,” said Seacoast’s President and CEO, Dr. Donald J. Larnard. “Brad’s experience and strategic approach make him an important addition to our Executive Team and an individual who will carry our technology effectively to the clinical and scientific communities.”

About Seacoast Technologies, Inc.

Seacoast Technologies is a neurosurgical and neurocritical care medical devices company using local and profound hypothermia to provide neuroprotection during neurosurgery and affect cerebral edema in post-surgical and emergency neurocritical care settings. Established in 2000, the Company has received IDE approval to begin clinical trials of its first product line, the ChillerStripTM system, designed to induce local and profound hypothermia to the brain during neurosurgery. Clinical trials at multiple centers in the U.S. will commence shortly.

For further information, see the company’s website at http://www.seacoasttechnologies.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brad Cilley
Visit website